-
.
-
.
it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done. .
.
![](/b98584f181.site.internapcdn.net/tmpl/v5/img/1x1.gif)
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance. .